Glatiramer Acetate






257 Article(s)
Download
PMID
Title
Journal
Pub. Date
#Total Relationship(s)
1 8793553 The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett 1996 Apr 1
2 9548401 Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur J Pharmacol 1998 Jan 26 1
3 9916886 Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998 Dec 1 3
4 10593303 Preliminary observations on APOE epsilon4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999 Dec 1
5 10619568 Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp Neurol 1999 Dec 2
6 10749576 Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000 Apr 2
7 10776827 What is new in the treatment of multiple sclerosis? Drugs 2000 Mar 1
8 10805349 Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial. Ann Neurol 2000 May 2
9 10900354 Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 2000 Aug 1 4
10 10961665 Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Neurosci Lett 2000 Aug 11 1
11 11027347 Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A 2000 Oct 10 4
12 11113226 Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000 Dec 12 2
13 11120865 Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J Immunol 2000 Dec 15 1
14 11212132 Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 2000 Dec 2
15 11223159 Glatiramer acetate blocks interleukin-1-dependent nuclear factor-kappaB activation and RANTES expression in human U-251 MG astroglial cells. Brain Res Mol Brain Res 2001 Feb 19 9
16 11287371 Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001 Apr 2
17 11389171 Glatiramer acetate inhibition of tumor necrosis factor-alpha-induced RANTES expression and release from U-251 MG human astrocytic cells. J Neurochem 2001 Jun 7
18 11525811 Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J Neuroimmunol 2001 Sep 3 7
19 11548979 Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001 Aug 1
20 11687463 Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol 2001 Nov 4
21 11809732 Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines. Int Immunol 2002 Feb 3
22 11877472 Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 2002 Mar 6
23 11971121 Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002 Apr 23 1
24 12020957 Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system. J Neuroimmunol 2002 May 1
25 12163197 Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002 Sep 15 2
26 12349849 Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Neurology 2002 Sep 24 2
27 12390966 Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002 Nov 7
28 12474988 Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002 Dec 4
29 12521562 Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol 2003 Jan 1
30 12572773 Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone). Folia Neuropathol 2002 5
31 12581542 A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther 2002 Dec 1
32 12668759 Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2003 Apr 15 1
33 12706402 In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clin Immunol 2003 Mar 4
34 12707324 Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003 May 1 6
35 12835817 [Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain]. Farm Hosp 2003 May-Jun 1
36 12882784 Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci 2003 Aug 1
37 12930374 Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol 2003 Sep 5
38 12962573 Modulation effects of human immature and mature dendritic cells on glatiramer acetate specific T cell lines in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003 Aug 5
39 14568126 Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003 Nov 15 1
40 14597106 Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. J Neuroimmunol 2003 Nov 3
41 14614135 Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003 Nov 25 4
42 14634263 Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur Neurol 2003 1
43 14704481 Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers. Pol J Pharmacol 2003 Sep-Oct 1
44 14732933 Immunomodulation by the copolymer glatiramer acetate. J Mol Recognit 2003 Nov-Dec 4
45 14760948 Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Mult Scler 2004 Feb 1
46 14975587 Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004 Mar 6
47 15090474 Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004 Jun 2
48 15153538 Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004 Jun 1 1
49 15218805 Immunologic factors in primary progressive multiple sclerosis. Mult Scler 2004 Jun 1
50 15223245 Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004 Jul 1